Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Featured Clinical Focus
Clinical Focus
News
Conferences
Media
Publications
Resources
Subscribe
  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • MJHLS Brand Logo

© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Featured Clinical Focus
  • AML
  • Biomarker-Driven Lung Cancer
  • Breast Cancer
  • CAR T-Cell Therapy
  • Chronic Lymphocytic Leukemia
  • EGFR+ Lung Cancer
  • Follicular Lymphoma
  • GI Cancers
  • HCC
  • HER2-Positive Breast Cancer
  • Lung Cancer
  • Lymphomas
  • Mantle Cell Lymphoma
  • MPNs
  • Multiple Myeloma
  • Prostate Cancer
  • Renal Cell Carcinoma
  • Thyroid Cancers
Clinical FocusSee All >
  • Brain Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancers
  • Hematology
  • Leukemias
  • Lung Cancer
  • Lymphomas
  • Melanoma
  • Sarcoma
  • Skin Cancers
  • Thyroid Cancers
baltimore conference logo
  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

The Next Steps for Bevacizumab in Recurrent Cervical Cancer

July 10, 2013
Krishnansu S. Tewari, MD
Krishnansu S. Tewari, MD

Krishnansu S. Tewari, MD, from the University of California, Irvine, comments on the next steps for bevacizumab for recurrent cervical cancer.

Krishnansu S. Tewari, MD, a professor of obstetrics and gynecology at the University of California, Irvine, comments on the next steps for bevacizumab for recurrent cervical cancer.

Data from a phase III trial were presented at a plenary session at the 2013 American Society of Clinical Oncology (ASCO) Meeting. The manuscript will be reviewed by the Gynecologic Oncology Group (GOG) publications committee, CTEP, and the NCI. Then, Tewari says, it will be reviewed by the journal chosen by the researchers.

Clinical Pearls

As for the regulatory aspects of the trial, Tewari says that he is unsure of the timeline. Genentech and Roche, the manufacturers of the molecule, will discuss the possibility of approval with the FDA.

  • Data were presented at the 2013 ASCO Meeting
  • Manuscripts will be reviewed by the GOG publications committee, CTEP, and NCI
  • Genentech and Roche, the manufacturers of the molecule, will discuss the possibility of approval with the FDA